Novamed, Sanofi say concerns raised in Brazil CADE market test are mitigated
By Maria Júlia Baumert ( September 8, 2026, 19:02 GMT | Insight) -- Novamed and Sanofi have responded to concerns raised by customers and competitors in a market test conducted by Brazil’s competition authority for its review of Novamed’s planned acquisition of Medley, Sanofi’s generic-drug business. The companies argued that the concerns are mitigated by the fragmented nature of the affected markets, the high substitutability of products, strong price competition and regulatory mechanisms that limit drug prices.Novamed and Sanofi have responded to concerns raised by customers and competitors in a market test conducted by Brazil’s competition authority for its review of Novamed’s proposed acquisition of Medley, Sanofi’s generic-drug business....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.